{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:14:46Z","timestamp":1790014486284,"version":"4.0.1"},"reference-count":115,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This article evaluates and summarizes key therapeutic advances and supportive care considerations for metastatic gastrointestinal stromal tumors (GISTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>GISTs comprise a highly aggressive, heterogeneous group of soft tissue sarcomas that span multiple anatomic origins. Following surgical resection, GISTs often recur locally or metastasize to the liver. Collectively, GISTs represent the first group of solid malignancies that was elucidated as a mutation-driven neoplasm more than 2 decades ago. The treatment landscape for GISTs shifted with the advent of kinase inhibitors (eg, imatinib and sunitinib) targeting the constitutive activation of the cognate receptor kinase encoded by the proto-oncogene KIT or PDGFRA, which enables tumor cells to proliferate in a ligand-independent manner. The critical relevance of these oncogenic signaling pathways and, most recently, the introduction of novel kinase inhibitors (eg, avapritinib) that target a common mutation (PDGFRA D842V) associated with primary resistance to imatinib, sunitinib, and regorafenib or development of secondary resistance (eg, to regorafenib or ripretinib) have refined the management of GISTs, including so-called \u201cwild-type\u201d GISTs. Although these results are promising, tumor heterogeneity and varied resistance mechanisms to kinase inhibitors across different tumor locations limit the efficacy of these therapies, highlighting the therapeutic need to develop novel therapies and the important role of supportive care in mitigating treatment-related adverse effects and prolonging life by minimizing treatment interruptions for a group of malignancies that are highly dependent on oncogenic signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Studies of the genomic and epigenetic landscape of GISTs have contributed to an understanding of their key molecular features and subsequent therapeutic advances. Supportive care is vital in optimizing treatment outcomes with these novel therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag245","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:46:07Z","timestamp":1787921167000},"source":"Crossref","is-referenced-by-count":0,"title":["Moving beyond a tale of two genes: Strides in management of metastatic gastrointestinal stromal tumors and their supportive care"],"prefix":"10.1093","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Houston Methodist West Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Albayeh","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center , Wichita, KS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026092113411005900_zxag245-B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"2026092113411005900_zxag245-B2","doi-asserted-by":"crossref","first-page":"e2428828","DOI":"10.1001\/jamanetworkopen.2024.28828","article-title":"Incidence and survival outcomes of gastrointestinal stromal tumors","volume":"7","author":"Alvarez","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026092113411005900_zxag245-B3","author":"Raut"},{"key":"2026092113411005900_zxag245-B4","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"2026092113411005900_zxag245-B5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2017.74.9705","article-title":"Gastrointestinal stromal tumors","volume":"36","author":"von Mehren","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5350","key":"2026092113411005900_zxag245-B6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"31","key":"2026092113411005900_zxag245-B7","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1200\/JCO.23.00213","article-title":"Flashback foreword: kinase mutations and imatinib response in patients with metastatic GI stromal tumor","volume":"41","author":"Maki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092113411005900_zxag245-B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2026092113411005900_zxag245-B9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"key":"2026092113411005900_zxag245-B10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-med-043010-091813","article-title":"The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy","volume":"63","author":"Joensuu","year":"2012","journal-title":"Annu Rev Med"},{"issue":"1","key":"2026092113411005900_zxag245-B11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.21160","article-title":"Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665","volume":"99","author":"Eisenberg","year":"2009","journal-title":"J Surg Oncol"},{"issue":"2","key":"2026092113411005900_zxag245-B12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gcc.2870010208","article-title":"Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene","volume":"1","author":"Stenman","year":"1989","journal-title":"Genes Chromosomes Cancer"},{"issue":"6061","key":"2026092113411005900_zxag245-B13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/320415a0","article-title":"A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family","volume":"320","author":"Besmer","year":"1986","journal-title":"Nature"},{"issue":"30","key":"2026092113411005900_zxag245-B14","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"2026092113411005900_zxag245-B15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.semdp.2006.08.006","article-title":"KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)","volume":"23","author":"Lasota","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"2026092113411005900_zxag245-B16","doi-asserted-by":"crossref","first-page":"927587","DOI":"10.3389\/fonc.2022.927587","article-title":"An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"key":"2026092113411005900_zxag245-B17","author":"Hemming"},{"key":"2026092113411005900_zxag245-B18","first-page":"1","article-title":"The GIST of advances in treatment of advanced gastrointestinal stromal tumor","volume":"42","author":"Schaefer","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"21","key":"2026092113411005900_zxag245-B19","doi-asserted-by":"crossref","first-page":"30109","DOI":"10.18632\/oncotarget.8768","article-title":"Concomitant KIT\/BRAF and PDGFRA\/BRAF mutations are rare events in gastrointestinal stromal tumors","volume":"7","author":"Rossi","year":"2016","journal-title":"Oncotarget"},{"key":"2026092113411005900_zxag245-B20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/annonc\/mdr127","article-title":"Prognostic value of KIT\/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience","volume":"23","author":"Wozniak","year":"2012","journal-title":"Ann Oncol"},{"key":"2026092113411005900_zxag245-B21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s12032-011-0074-y","article-title":"Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs","volume":"29","author":"Emile","year":"2012","journal-title":"Med Oncol"},{"key":"2026092113411005900_zxag245-B22","doi-asserted-by":"crossref","first-page":"1758835920986498","DOI":"10.1177\/1758835920986498","article-title":"Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward","volume":"13","author":"Lostes-Bardaji","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2026092113411005900_zxag245-B23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.pas.0000146010.92933.de","article-title":"Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2026092113411005900_zxag245-B24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00000478-200604000-00008","article-title":"Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2026092113411005900_zxag245-B25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"2026092113411005900_zxag245-B26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","article-title":"KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours","volume":"42","author":"Debiec-Rychter","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"2026092113411005900_zxag245-B27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"33","key":"2026092113411005900_zxag245-B28","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","article-title":"Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026092113411005900_zxag245-B29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients","volume":"28","author":"Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092113411005900_zxag245-B30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026092113411005900_zxag245-B31","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026092113411005900_zxag245-B32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2025.05.535","article-title":"Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial","volume":"36","author":"Blay","year":"2025","journal-title":"Ann Oncol"},{"key":"2026092113411005900_zxag245-B33","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/jco.2004.22.90140.3012","article-title":"Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning","volume":"22","author":"Van Den Abbeele","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092113411005900_zxag245-B34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12029-013-9532-4","article-title":"Reintroduction of imatinib in GIST","volume":"44","author":"Reid","year":"2013","journal-title":"J Gastrointest Cancer"},{"issue":"12","key":"2026092113411005900_zxag245-B35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1470-2045(13)70453-4","article-title":"Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial","volume":"14","author":"Kang","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9440","key":"2026092113411005900_zxag245-B36","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"2026092113411005900_zxag245-B37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-013-2135-8","article-title":"Long-term efficacy of imatinib for treatment of metastatic GIST","volume":"72","author":"Patel","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"2026092113411005900_zxag245-B38","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor \u03b1-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2026092113411005900_zxag245-B39","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026092113411005900_zxag245-B40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4143\/crt.2015.015","article-title":"Efficacy of imatinib in patients with platelet-derived growth factor receptor \u03b1-mutated gastrointestinal stromal tumors","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"7","key":"2026092113411005900_zxag245-B41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026092113411005900_zxag245-B42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","article-title":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial","volume":"145","author":"Jones","year":"2021","journal-title":"Eur J Cancer"},{"issue":"28","key":"2026092113411005900_zxag245-B43","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026092113411005900_zxag245-B44","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.esmoop.2021.100159","article-title":"The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842\u2005V mutation","volume":"6","author":"Trullas-Jimeno","year":"2021","journal-title":"ESMO Open"},{"issue":"11","key":"2026092113411005900_zxag245-B45","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2026092113411005900_zxag245-B46","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","article-title":"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib","volume":"23","author":"Corless","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026092113411005900_zxag245-B47","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.2147\/OTT.S101385","article-title":"Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives","volume":"9","author":"Mulet-Margalef","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2026092113411005900_zxag245-B48","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3390\/cancers15072074","article-title":"Molecular tailored therapeutic options for advanced gastrointestinal stromal tumors (GISTs): current practice and future perspectives","volume":"15","author":"Catalano","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"2026092113411005900_zxag245-B49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J Pathol"},{"issue":"5","key":"2026092113411005900_zxag245-B50","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"2026092113411005900_zxag245-B51","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","article-title":"Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy","volume":"27","author":"Ben-Ami","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"2026092113411005900_zxag245-B52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"issue":"24","key":"2026092113411005900_zxag245-B53","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1200\/JCO.2008.21.3330","article-title":"Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial","volume":"27","author":"Le Cesne","year":"2009","journal-title":"J Clin Oncol"},{"issue":"34","key":"2026092113411005900_zxag245-B54","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.22.00294","article-title":"Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial","volume":"40","author":"Bauer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026092113411005900_zxag245-B55","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"2026092113411005900_zxag245-B56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2407-12-107","article-title":"The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure\u2014one institution study","volume":"12","author":"Rutkowski","year":"2012","journal-title":"BMC Cancer"},{"issue":"9","key":"2026092113411005900_zxag245-B57","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/cncr.29220","article-title":"Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib","volume":"121","author":"Reichardt","year":"2015","journal-title":"Cancer"},{"key":"2026092113411005900_zxag245-B58","author":"Sutent (sunitinib)"},{"issue":"5","key":"2026092113411005900_zxag245-B59","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2026092113411005900_zxag245-B60","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"issue":"9863","key":"2026092113411005900_zxag245-B61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"2026092113411005900_zxag245-B62","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","article-title":"The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?","volume":"91","author":"Ho","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2026092113411005900_zxag245-B63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.36401\/JIPO-20-21","article-title":"Targeted cancer therapy and its ophthalmic side effects: a review","volume":"4","author":"Bindiganavile","year":"2021","journal-title":"J Immunother Precis Oncol"},{"issue":"3","key":"2026092113411005900_zxag245-B64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"2026092113411005900_zxag245-B65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","article-title":"Practical management of tyrosine kinase inhibitor-associated side effects in GIST","volume":"37","author":"Joensuu","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2026092113411005900_zxag245-B66","doi-asserted-by":"publisher","DOI":"10.54844\/git.2023.482","article-title":"Safety outcomes of low versus high dose imatinib mesylate in patients with advanced, metastatic, or nonresectable gastrointestinal stromal tumors: a systematic review","volume":"2","author":"Marucci","year":"2024","journal-title":"Gastrointest Tract"},{"issue":"6","key":"2026092113411005900_zxag245-B67","doi-asserted-by":"crossref","first-page":"e27531","DOI":"10.1016\/j.heliyon.2024.e27531","article-title":"Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"2026092113411005900_zxag245-B68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"46","key":"2026092113411005900_zxag245-B69","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.3748\/wjg.v24.i46.5189","article-title":"Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors","volume":"24","author":"Li","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2026092113411005900_zxag245-B70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.critrevonc.2014.01.002","article-title":"Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group","volume":"91","author":"Sodergren","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"2026092113411005900_zxag245-B71","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0959-8049(02)00836-5","article-title":"Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study","volume":"39","author":"Verweij","year":"2003","journal-title":"Eur J Cancer"},{"issue":"11","key":"2026092113411005900_zxag245-B72","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"issue":"16","key":"2026092113411005900_zxag245-B73","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2017.77.1485","article-title":"Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma","volume":"36","author":"Jonasch","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026092113411005900_zxag245-B74","first-page":"375","article-title":"Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study","volume":"31","author":"Shou","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026092113411005900_zxag245-B75","doi-asserted-by":"crossref","first-page":"S1267","DOI":"10.1016\/j.annonc.2022.07.1672","article-title":"Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials","volume":"33","author":"Pandy","year":"2022","journal-title":"Ann Oncol"},{"key":"2026092113411005900_zxag245-B76","author":"Qinlock (ripretinib)"},{"issue":"5","key":"2026092113411005900_zxag245-B77","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/1759-7714.12608","article-title":"Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors","volume":"9","author":"Fu","year":"2018","journal-title":"Thorac Cancer"},{"issue":"4","key":"2026092113411005900_zxag245-B78","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2026092113411005900_zxag245-B79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J Support Oncol"},{"issue":"2","key":"2026092113411005900_zxag245-B80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"issue":"5","key":"2026092113411005900_zxag245-B81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.12.29","article-title":"Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors","volume":"8","author":"Li","year":"2012","journal-title":"Future Oncol"},{"key":"2026092113411005900_zxag245-B82","author":"Gleevec (imatinib)"},{"key":"2026092113411005900_zxag245-B83","doi-asserted-by":"crossref","first-page":"1190123","DOI":"10.3389\/fonc.2023.1190123","article-title":"Case report: should regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on regorafenib personalized schedule","volume":"13","author":"Grimaudo","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"2026092113411005900_zxag245-B84","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"2026092113411005900_zxag245-B85","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2026092113411005900_zxag245-B86","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1093\/ajhp\/zxaf282","article-title":"Rising with cardio-oncology: clinical considerations of cardiotoxicity with select anticancer drug therapies","volume":"83","author":"Chung","year":"2026","journal-title":"Am J Health-Syst Pharm"},{"issue":"36","key":"2026092113411005900_zxag245-B87","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026092113411005900_zxag245-B88","author":"Stivarga (regorafenib)"},{"key":"2026092113411005900_zxag245-B89","volume-title":"Package","author":"Ayvakit (avapritinib)"},{"issue":"11","key":"2026092113411005900_zxag245-B90","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-11-3005","article-title":"Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure","volume":"18","author":"Demetri","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"15 suppl","key":"2026092113411005900_zxag245-B91","doi-asserted-by":"crossref","first-page":"e21113","DOI":"10.1200\/jco.2011.29.15_suppl.e21113","article-title":"Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST)","volume":"29","author":"Puzanov","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092113411005900_zxag245-B92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2026092113411005900_zxag245-B93","first-page":"18413","article-title":"Consumptive hypothyroidism due to a gastrointestinal stromal tumor expressing type 3 iodothyronine deiodinase","volume":"8","author":"Yan","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"2026092113411005900_zxag245-B94","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1002\/onco.13632","article-title":"Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors","volume":"26","author":"Joseph","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"2026092113411005900_zxag245-B95","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1038\/s41598-025-86959-z","article-title":"Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system","volume":"15","author":"Mao","year":"2025","journal-title":"Sci Rep"},{"issue":"11","key":"2026092113411005900_zxag245-B96","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s11864-024-01272-7","article-title":"Current drug resistance mechanisms and treatment options in gastrointestinal stromal tumors: summary and update","volume":"25","author":"He","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2026092113411005900_zxag245-B97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41419-024-06571-3","article-title":"Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"issue":"7","key":"2026092113411005900_zxag245-B98","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/pharmaceutics17070923","article-title":"Tyrosine kinase inhibitors for gastrointestinal stromal tumor after imatinib resistance","volume":"17","author":"Xiao","year":"2025","journal-title":"Pharmaceutics"},{"issue":"10","key":"2026092113411005900_zxag245-B99","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"23 suppl","key":"2026092113411005900_zxag245-B100","doi-asserted-by":"crossref","first-page":"TPS97","DOI":"10.1200\/JCO.2024.42.23_suppl.TPS97","article-title":"CHAPTER-GIST-101: a phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor","volume":"42","author":"Hirano","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026092113411005900_zxag245-B101","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","article-title":"Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial","volume":"33","author":"Kurokawa","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"2026092113411005900_zxag245-B102","doi-asserted-by":"crossref","first-page":"106088","DOI":"10.1016\/j.esmoop.2026.106088","article-title":"Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study","volume":"11","author":"Komatsu","year":"2026","journal-title":"ESMO Open"},{"issue":"7","key":"2026092113411005900_zxag245-B103","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1158\/2159-8290.CD-21-0646","article-title":"MOZ and menin-MLL complexes are complementary regulators of chromatin association and transcriptional output in gastrointestinal stromal tumor","volume":"12","author":"Hemming","year":"2022","journal-title":"Cancer Discov"},{"issue":"8","key":"2026092113411005900_zxag245-B104","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"2026092113411005900_zxag245-B105","author":"Komzifti (ziftomenib)"},{"key":"2026092113411005900_zxag245-B106","doi-asserted-by":"crossref","first-page":"114745","DOI":"10.1016\/j.ejca.2024.114745","article-title":"227 (PB215): menin inhibitor ziftomenib synergizes with imatinib in tyrosine kinase inhibitor (TKI)-resistant gastrointestinal stromal tumor models","volume":"211","author":"McCloskey","year":"2024","journal-title":"Eur J Cancer"},{"issue":"16 suppl","key":"2026092113411005900_zxag245-B107","first-page":"TPS11578","article-title":"Phase 1a\/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026092113411005900_zxag245-B108","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-13-0765","article-title":"Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA","volume":"19","author":"Maier","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026092113411005900_zxag245-B109","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","article-title":"The management of metastatic GIST: current standard and investigational therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2026092113411005900_zxag245-B110","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3748\/wjg.v21.i8.2303","article-title":"Succinate dehydrogenase-deficient gastrointestinal stromal tumors","volume":"21","author":"Wang","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2026092113411005900_zxag245-B111","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-21-2092","article-title":"Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor models for predicting therapeutic response","volume":"28","author":"Yebra","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026092113411005900_zxag245-B112","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.21037\/tcr-21-131","article-title":"Succinate dehydrogenase-deficient gastrointestinal stromal tumor: from diagnostic dilemma to novel personalised therapy in 2 case reports","volume":"10","author":"De Silva","year":"2021","journal-title":"Transl Cancer Res"},{"key":"2026092113411005900_zxag245-B113","doi-asserted-by":"crossref","first-page":"768765","DOI":"10.3389\/fpubh.2021.768765","article-title":"Cost-effectiveness analysis of tyrosine kinase inhibitors in gastrointestinal stromal tumor: a systematic review","volume":"9","author":"Feng","year":"2022","journal-title":"Front Public Health"},{"issue":"9","key":"2026092113411005900_zxag245-B114","doi-asserted-by":"crossref","first-page":"e2013565","DOI":"10.1001\/jamanetworkopen.2020.13565","article-title":"Cost-effectiveness analysis of genetic testing and tailored first-line therapy for patients with metastatic gastrointestinal stromal tumors","volume":"3","author":"Banerjee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026092113411005900_zxag245-B115","doi-asserted-by":"crossref","first-page":"103477","DOI":"10.1016\/j.esmoop.2024.103477","article-title":"Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes","volume":"9","author":"Giraud","year":"2024","journal-title":"ESMO Open"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag245\/70826944\/zxag245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag245\/70826944\/zxag245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:41:32Z","timestamp":1790012492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag245\/8772262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":115,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag245","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"zxag245"}}